

1	Type of Issue (IPO / FPO)	IPO
2	Issue Size (Rs. mn)	64,795.45

3 Grade of issue along with name of the rating agency

Name	NA
Grade	NA

4	Subscription Level (Number of times)	2.03
---	--------------------------------------	------

Notes:

*Source: Basis of Allotment

5 QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges

Particulars	%age
(i) allotment in the issue ⁽¹⁾	22.54%
(ii) at the end of the 1st Quarter immediately after the listing of the issue	23.54%
(iii) at the end of 1st FY (March 31, 2021)	23.12%
(iv) at the end of 2nd FY (March 31, 2022)	23.18%
(v) at the end of 3rd FY (March 31, 2023)	23.33%

Source:

(1) Exchange Filings

6 Financials of the issuer

Parameters	(Rs. mn)		
	1st FY(March 31, 2021)	2nd FY(March 31, 2022)	3rd FY(March 31, 2023)
Income from operations	34,629	44,007	36,246
Net Profit for the period	9,970	12,117	7,810
Paid up Equity Share Capital	164	164	165
Reserves excluding revaluation reserves	58,869	71,412	79,423

7 Trading Status in the scrip of the issuer



Company's Equity Shares are listed on BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE")

Particulars	Status
(i) at the end of 1st FY (March 31, 2021)	Frequently traded
(ii) at the end of 2nd FY (March 31, 2022)	Frequently traded
(iii) at the end of 3rd FY (March 31, 2023)	Frequently traded

8 Change in Directors of Issuer from the disclosures in the offer document

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2021)	Ms Naina Lal Kidwai	Appointed
	Dr. Allen Zhang	Appointed
(ii) at the end of 2nd FY (March 31, 2022)	Mr. Yao Fang	Appointed
	Mr. Li Dongming	Resignation
(iii) at the end of 3rd FY (March 31, 2023)	No Change	No Change

9 Status of implementation of project/ commencement of commercial production

(i) Details of Estimated Schedule of Implementation of Projects forming part of the Objects of the issue as per Prospectus	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) As disclosed in the offer document Deploy INR 7,783.51 mn in FY21 and INR 4,456.17 mn in FY22 ⁽¹⁾

(ii) Actual utilization ⁽²⁾ INR 12,250.00mn utilised⁽³⁾

(iii) Reasons for deviation, if any ⁽²⁾ No Deviation from Objects

(1) Revised to deploy INR 7,793.83 mn in FY21 and INR 4,456.17 mn in FY22

(2) Statement of Deviation or Variation of Funds Dated 26th October, 2022

(3) The actual issue expenditure concluded at INR 250mn as against estimated amount of INR 260mn, pursuant to which the unutilised portion of issue expenses of INR 10mn were added to the Net proceeds for the general corporate purpose resulting in balance available for utilisation being revised to INR 2,875mn from INR 2,865mn

11 Comments of monitoring agency, if applicable*

(i) Comments on use of funds None

(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document None

(iii) Any other reservations expressed by the monitoring agency about the end use of funds None

* As per Monitoring Report by Axis Bank Ltd.

12 Pricing Data



Issue Price (Rs.) 1500.00
 Designated Stock Exchange: BSE
 Listing Date: 20-Nov-20

Price parameters	At close of listing day	Close of 30th calendar day from listing day December 20, 2020	Close of 90th calendar day from listing day February 18, 2021	At the end of FY 2021		
				Closing price	High	Low
Market Price (BSE)	1,820.45	2,315.00	2,449.40	2,477.80	2,784.45	1,701.00
BSE Sensex	43,882.25	45,553.96	51,324.69	49,509.15	52,516.76	27,500.79
Price parameters	At the end of FY 2022			At the end of FY 2023		
	Closing price	High	Low	Closing price	High	Low
Market Price (BSE)	3,269.15	4,350.00	2,411.00	1,268.25	3,556.10	1,130.05
BSE Sensex	58,568.51	62,245.43	47,204.50	58,991.52	63,583.10	50,921.20

Source: BSE Website

13 Basis for Issue Price and Comparison with Peer Group & Industry Average

Not Applicable as there are no listed companies in India that engage in a business similar to that of the company

14 Any other material information

Particulars	Date	Remarks
Board re-appointed Mr. Srinivas Sadu as Managing Director and CEO of the Company for a period of 5 years w.e.f. April 25, 2022 and appointed Mr. Yao Fang as an Additional Director categorized as Non-Independent and Non-Executive Director w.e.f. March 10, 2022, while Mr. Li Dongming resigned w.e.f. March 10, 2022.	10-Mar-22	
Allotment of 79,400 Equity shares under ESOP	15-Jun-22	
US FDA Inspection	25-Aug-22	
Allotment of 32,500 Equity shares under ESOP	15-Sep-22	
US FDA Inspection	27-Jan-23	
US FDA Inspection	27-Jun-23	
US FDA Inspection	14-Jul-23	
US FDA Inspection	28-Jul-23	
Board appointed Mr. Prakash Vithal Baliga as Chief Operating Officer of the Company w.e.f. August 07, 2023	07-Aug-23	
US FDA Inspection	24-Aug-23	
US FDA Inspection	26-Aug-23	
Mr. Ankit Gupta has been appointed as Vice-President (Strategy & Investments), a Senior Management Personnel of the Company, effective 04th September, 2023	04-Sep-23	
US FDA Inspection	26-Sep-23	
ESOP Compensation Committee of the Board of Directors of the Company has allotted 1,100 Equity shares of Re.1/- each of the Company, fully paid up, on October 10, 2023 to employee(s) on exercise of their Stock Options pursuant to Gland Pharma Employee Stock Options Scheme, 2019	10-Oct-23	
Board re-appointed Mr. Satyanarayana Murthy Chavali as an Independent Director for a period of 5 years, w.e.f. 20th November 2023	17-Oct-23	
US FDA Inspection	08-Nov-23	
US FDA Inspection	24-Nov-23	

Note: For further updates and information, please refer stock exchange websites i.e. www.bseindia.com and www.nseindia.com

DISCLAIMER:

The information disclosed on this website has been uploaded by Citigroup Global Markets India Private Limited ("Citi") solely pursuant to the requirements of the SEBI Circular No. CIR/MIRSD/1/2012 dated January 10, 2012 (the "Circular") for the limited purpose of the Circular, without having regard to specific objectives, suitability, financial situations or the needs of any particular person, and does not constitute any recommendation, and should not be construed as an offer to sell or the solicitation of an offer to buy, purchase or subscribe to any securities mentioned herein. Neither this information, nor anything else contained on this website, shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. Nothing in this information is intended by Citi to be construed as legal, regulatory, accounting, tax or other advice. Past performance is not necessarily a guide for future performance.

The information disclosed on this website has been collated from different sources, including, but not limited to, information obtained from the websites of the BSE Limited (www.bseindia.com), The National Stock Exchange of India Limited (www.nseindia.com), websites of the respective issuer companies, annual reports of the issuer companies, certain databases such as "www.capitalmarkets.com" and post issue reports filed with Securities and Exchange Board of India. Neither Citi, its affiliates nor any of their respective directors, employees, agents or representatives makes any implicit or explicit representation or warranty regarding the accuracy or completeness of the information or accepts or assumes any responsibility for the accuracy or completeness of the information or any loss whether direct or indirect, incidental, special or consequential that may arise from or in connection with the use of this information or otherwise.

The information disclosed on this website is updated as of February 02, 2024. Citi does not undertake to update the information contained herein except as required by applicable law or regulation.